# Imperialumab
This report analyses the return phase performance of this drug to investigate the cause of it's declining growth rate and understand how the market positioning and promotional campaigns can be structured so as to sustain the growth rate of Imperialumab's sales in the remaining period of its patent before it becomes genericised
